NCT00217529View on ClinicalTrials.gov

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2005

Conditions

Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer

Interventions

BIOLOGICAL

pegfilgrastim

DRUG

carboplatin

DRUG

docetaxel

DRUG

erlotinib hydrochloride

Trial Locations (3)

98104

Pacific Gynecology Specialists, Seattle

98195

University of Washington School of Medicine, Seattle

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors

lead

Fred Hutchinson Cancer Center

OTHER

NCT00217529 - Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter